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OBJECTIVE
Type 2 diabetes is a growing health problem among both adults and adolescents. To
betterunderstand thedifferences in thepathogenesisofdiabetesbetween thesegroups,
we examined differences in b-cell function along the spectrum of glucose tolerance.
RESEARCH DESIGN AND METHODS
We evaluated 89 adults and 50 adolescents with normal glucose tolerance (NGT),
dysglycemia, or type 2 diabetes. Oral glucose tolerance test results were used for
C-peptide and insulin/glucose minimal modeling. Model-derived and direct mea-
sures of insulin secretion and insulin sensitivity were compared across glycemic
stages and between age-groups at each stage.
RESULTS
In adolescents with dysglycemia, there was marked insulin resistance (insulin sensi-
tivity index: adolescents, median [interquartile range] 1.8 [1.1–2.4]3 1024; adults,
5.0 [2.3–9.9]; P = 0.01). The nature ofb-cell dysfunction across stages of dysglycemia
differed between the groups. We observed higher levels of secretion among adoles-
cents thanadults (total insulin secretion:NGT, 143 [103–284]3 1029/min adolescent
vs. 106 [71–127], P = 0.001); adults showed stepwise impairments in static insulin
secretion (NGT, 7.5 [4.0–10.3] 3 1029/min; dysglycemia, 5.0 [2.3–9.9]; type 2 di-
abetes, 0.7 [0.1–2.45]; P = 0.003), whereas adolescents showed diabetes-related
impairment in dynamic secretion (NGT, 1,905 [1,630–3,913] 3 1029; dysglycemia,
2,703 [1,323–3,637]; type 2 diabetes, 1,189 [269–1,410]; P = 0.001).
CONCLUSIONS
Adults and adolescents differ in the underlying defects leading to dysglycemia, and in
the nature of b-cell dysfunction across stages of dysglycemia. These results may
suggest different approaches to diabetes prevention in youths versus adults.
The progression from normal glucose tolerance (NGT) through dysglycemia (impaired
fasting and/or impaired glucose tolerance [IGT]) to type 2 diabetes is marked by con-
current changes in insulin sensitivity andb-cell function (i.e., insulin secretion).Models
based on longitudinal data suggest that changes in insulin sensitivity dominate the tran-
sition from NGT to dysglycemia, whereas changes in b-cell function drive the transition
fromdysglycemia toovert diabetes (1). These components are interdependent,with the
magnitude of insulin secretion determined in part by the ambient insulin sensitivity.
This interdependence is capturedby thedisposition index (DI), a numerical product of the
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two parameters,which aids in distinguishing
appropriate compensatory changes from in-
sufficient compensation (2). DIs have been
constructed from direct measures of in-
sulin secretion and insulin sensitivity (e.g.,
using glucose clamp methodology) or
from measures derived from mathemati-
cal models based on biochemical excur-
sions after intravenous or oral glucose
loading (3).
In adolescent type 2 diabetes, alarming
trends in clinical progressionandoutcomes
have been recently observed, in particular
what appears to bemarkedlymore aggres-
sive disease progression compared with a
more indolent and gradual process among
adults (4–6). Variations in the balance of
b-cell dysfunction and insulin resistance (IR)
thatunderlie statesofdysglycemiahavebeen
described in adult populations (7–9) and in
the growing population of pediatric par-
ticipants at risk for, or with, type 2 diabe-
tes (10–12). Puberty-related IR is a b-cell
stressor exclusive to adolescents, which
may produce unique patterns in the path-
ogenesis and advance of dysglycemia.
These observations call for a better un-
derstanding of the pathogenesis of dys-
glycemia and how itmight differ between
youths andadults. There are very fewdata
providing direct comparisons of adults
and youths across the spectrum of glyce-
mia. Here we have undertaken compari-
sons of overweight or obese adults and
youths with normoglycemia, dysglycemia
(impaired fasting glucose or IGT), and
type 2 diabetes using standardized oral
glucose tolerance testing and mathemat-
icalmodeling toderivedetailedphenotypes
of b-cell function. We hypothesized that
obese youths and adults would show in-
formative differences in the pattern of
b-cell dysfunction across the clinical spec-
trum of glucose tolerance. These efforts
provide key information that may help
guideus towardmoreeffectiveage-specific
treatment or prevention interventions.
RESEARCH DESIGN AND METHODS
Participants
We analyzed data from physiologic stud-
ies performed at Indiana University from
2009through2012, someportionsofwhich
have been previously published (13–16).
The individual studies and the aggrega-
tion of study data into a cross-sectional
data set for analyses such as those pre-
sented herewere approvedby the institu-
tional review board at Indiana University.
Written informed consent was obtained
from all participants, including approval
for the use of their data in analyses un-
related to the primary study.
Pubertal adolescents#18 years of age
with a BMI.95th percentile for age and
sex presented for the evaluation and
treatmentof obesity at a tertiary care spe-
cialty clinic and were offered an opportu-
nity to participate; the youngest age of
ourparticipantswas12years.Tanner stag-
ingwas performed clinically as part of those
visits. Individuals with syndromic obesity,
chronic disease, or long-term medication
use interfering with endocrine function
or glucose regulation were excluded. Dia-
betes status was determined by prior
physician diagnosis or was defined with
protocol testing using a 2-h 75-g oral glu-
cose tolerance test (OGTT) performed un-
der fasting conditions (detailed below),
applying theAmericanDiabetesAssociation
criteriaof fastingglucose level.126mg/dL
or 2-h glucose level.200 mg/dL.
Adult subjects presented for participa-
tion in ongoing clinical studies of glucose
metabolism, with inclusion criteria of
age.18 years, nonpregnant, nonsmoker,
with no chronic illnesses or use of medi-
cations that affect glucose metabolism.
The current analyses included only over-
weight or obese individuals (BMI.25 kg/
m2). Adult BMI z scores were assigned
using 2012 National Health and Nutrition
Examination Survey data on the national
distribution of BMI values. Diabeteswas de-
termined as described above, using clinical
diagnoses or data from the OGTT per-
formed under the study protocols. Partici-
pants with diabetes were excluded if they
had been treated with a thiazolidinedione
within 6 months of the plannedmeasure-
ments (given the sustained effects of
these agents to alter the endogenous
metabolic balance) or if their fasting glu-
cose level on the morning of the planned
glucose tolerance test exceeded 300 mg/
dL (to mitigate the risk of marked hyper-
glycemia after glucose ingestion). In both
populations, oral antidiabetic medica-
tions were withheld for a minimum of
24 h or three half-lives prior to glucose
tolerance testing. No insulin-treated par-
ticipants were studied.
Procedures
Study procedures for adolescents were
performed at the Indiana Clinical and
Translational Sciences Institute Clinical
Research Center after an overnight fast.
Age was determined to the nearest year;
weight and height were determined to
the nearest 0.1 kg and 0.1 cm, respec-
tively; and resting blood pressure was
measured with an anaeroid sphygmoma-
nometer on the upper arm using an ap-
propriately sized cuff. Fasting blood was
sampled for measurement of fasting in-
sulin, C-peptide, glucose, and other ana-
lytes. Next, a standard 75-g OGTT was
performed, with serum glucose, insulin,
and C-peptide sampled at times 215, 0,
15, 30, 60, 90, and 120 min.
Study procedures for adults were also
performedat the IndianaClinical andTrans-
lational Sciences Institute Clinical Research
Center after an overnight fast. The proce-
dures performed paralleled those for the
adolescents, except that the timing for
the sampling with the 75-g OGTT differed,
with sampling at times of 215, 0, 10, 20,
30, 60, 90, 120, and 180 min. These dif-
ferences in timing arose as a result of
differences in the original protocols con-
tributing data.
Fasting lipids and liver enzymes were
performed in the IndianaUniversity Health
Pathology Laboratory using standard
methodologies for all subjects. Glucose
measurements were performed at the
bedside using a glucose oxidase method
(within-runCV2%) (YSI 2700STATGlucose
Analyzer; Yellow Springs Instruments, Yel-
lowSprings, OH). The IndianaDiabetes Re-
search Center Translation Core performed
measurements of glucose (pediatric par-
ticipants; glucose oxidase method) (RX
Daytona; Randox, Crumlin, U.K.; CV 4.5%),
insulin (radioimmunoassay; Millipore/
Linco, St. Charles, MO; intra-assay CV 2.2–
4.4%), and C-peptide (radioimmunoassay;
Millipore/Linco; intra-assay CV 3.4–6.4%).
Assessment of b-Cell Function
Direct Measures
We calculated traditional measures of
insulin secretion and IR from the OGTT
data, including the homeostasis model
IR index HOMA-IR, insulinogenic index
(IGI [(Ins302 Ins0)/(Gluc302 Gluc0)]), and
C-peptide index (CPI [(Cpep30 2 Cpep0)/
(Gluc302 Gluc0)]).
Model-Derived Measures
Insulin sensitivitywas estimatedusing the
oral insulin/glucoseminimal model, while
insulin secretion measures were derived
from the oral C-peptide minimal model,
both using SAAM II software (version
2.3.1.1; The Epsilon Group, Charlottes-
ville, VA). The oralminimalmodel is based
on a single-compartment system with a
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single input via the ingested glucose dose,
modeling a monophasic glucose time
course (3). This modeling approach has
been extensively validated and is argu-
ably preferable over simpler approaches
to measurement of b-cell function, as re-
viewed by Cobelli et al. (3). In a minority
of cases, the experimental data exhibited
nonmonophasic glucose curves, typically
failing to fall monotonically over the
late interval of observation. Such data
proved difficult to model. Therefore, if a
second rise in glucose, defined as an
increase .4.5 mg/dL above a previous
nadir (17–19), was evident, we truncated
the modeled experiment length to cap-
ture the first rise and fall of glucose as
monophasic. In these instances andwhere
otherwise necessary, modeling equa-
tionswere adjusted as previously described
(20) for variations in sampling times
andexperiment lengths.Measuredglucose,
insulin, and C-peptide concentrations
during 2- and 3-h OGTT for adoles-
cents and adults, respectively, were used
as the known input, and glucose deriva-
tives were calculated using MATLAB soft-
ware (R2016a, version 9.0.0.341360;
MathWorks, Natick, MA). All baseline in-
puts (gss, Ib, Cpb) were taken as the
mean of measured values at t = 215 and
t = 0. Where t = 215 data were missing,
datapoints at t =0were taken as the basal
value (21). Areaunder the curve for glucose
was calculated using the trapezoidal equa-
tion. Body volume used in the C-peptide
modelwas calculated, andC-peptidekinetic
parameters FRA andA1were designated as
previously described (22).
These models produced estimates for
each participant of Si (the insulin sensitiv-
ity index),Fd (dynamic insulin secretion;
reflecting changes in secretion in re-
sponse to immediate changes in glucose),
Fs (static insulin secretion; reflecting in-
sulin secretion distinct from the dynamic
response), andFt (total insulin secretion;
incorporating bothFs andFd) (3,23). DIs
were then calculated from these mea-
surements by combining modeled F
with modeled Si (3).
Statistics
Statistical analyses were performed us-
ing SPSS software (version 24.0; IBM,
Armonk, NY). All data were presented as
themean6 SD,where applicable. Patient
characteristics were compared using x2
analyses and one-way ANOVA as ap-
propriate. Theadolescent BMIwas further
expressed as the BMI SD score, and ado-
lescent blood pressure was expressed as
the percentile per norms for age, sex, and
height (24). Patients were characterized
as being normal, having dysglycemia
(IGT; 2-h glucose .140 mg/dL or im-
paired fasting glucose; fasting glucose
.100 mg/dL), or having type 2 diabetes
(pre-existing diagnosis or by study OGTT
using American Diabetes Association glu-
cose criteria) (25). Measures of b-cell
function and insulin sensitivity were com-
pared within and between each age cat-
egory using one- and two-way ANOVA.
Non-normally distributed parameters
were log transformed before analysis;
data are presented as nontransformed
values for clarity. Additionally, because
the groups differed significantly by obe-
sity measures despite the exclusion of
lean individuals, all analyses presented in-
cluded an adjustment for BMI z score.
Parallel analyses were also performed ad-
justing for BMI directly, without material
differences in the overall pattern of sig-
nificant differences (data not shown).
The primary comparison of interest was
the interaction of age and glycemic cate-
gory, asking whether the pattern of
change across glycemic categories differed
between adults and adolescents. P# 0.05
was considered statistically significant.
RESULTS
Patient Characteristics
Eighty-nine overweight and obese adults
(BMI 31.5 6 6.7 kg/m2 [mean 6 SD];
39.6% female) 47.1 6 10.4 years of age
(age range 26–66 years) and 50 obese ad-
olescents (BMI 39.0 6 8.2 kg/m2, 52%
female) 14.4 6 1.7 years of age (age
range 12–18 years) with sufficient data
for at least one minimal model were in-
cluded. Sensitivity analyses incorporating
sex or ethnicity as covariates did not
meaningfully alter the results. Conse-
quently, the results that follow are not
adjusted for sex or ethnicity. As described
above, all between-group comparisons
were adjusted for BMI z scores owing to
the different degrees of obesity in the
adult and adolescent cohorts.
Data from81adults and43 adolescents
were available for paired C-peptide and
insulin/glucose minimal modeling, allow-
ing the calculationofmodel-derivedDIs in
these individuals. The anthropometric
and metabolic characteristics of this ma-
jority subset did not differ from the com-
plete group (data not shown).
Patient characteristics are summarized
in Table 1. Adolescents with NGT and dys-
glycemia had higher BMI andBMI z scores
compared with adults at similar clinical
stages. Adolescents with NGT and dysgly-
cemia also had higher fasting insulin
concentrations than adults at the same
clinical stage, whereas youths with diabe-
tes had lower HbA1c levels than adults
with diabetes. Adolescents had lower total
cholesterol than adults at all stages, but ad-
olescents with dysglycemia also had higher
triglyceride and lowerHDL levels than adults
with dysglycemia. Themean systolic and di-
astolic blood pressure percentiles were
higher in adolescents with dysglycemia
than in those with normoglycemia (systolic
blood pressure P = 0.001; diastolic blood
pressure P = 0.005) butwere not different
between youths with dysglycemia and
those with type 2 diabetes. Systolic blood
pressure was significantly higher in adults
with diabetes than in those with dysgly-
cemia (P = 0.047), but systolic and dia-
stolic blood pressure did not otherwise
differ between adult categories.
Differences Across Glycemic Stages
Measures of b-cell function and insulin
sensitivity are presented in Figs. 1 and 2
and Table 2. Statistical comparisons of
these measures were adjusted for BMI z
score. In the overweight and obese adults
studied, measures of insulin sensitivity
did not differ between normoglycemic
individuals and those with dysglycemia. In
adults with type 2 diabetes, however, Si
was lower and HOMA-IR higher than in
normoglycemic subjects or subjects with
dysglycemia (all P , 0.001). The b-cell
function measures IGI and CPI, and their
respective DIs, showed stepwise de-
creases across worsening clinical stages
(NGT vs. dysglycemia P , 0.05; NGT vs.
diabetes, and dysglycemia vs. diabetes,
all P , 0.001). Model-derived measures
followed a parallel pattern, as follows:
Ft was lower in each successive clinical
stage (NGTvs. dysglycemia P = 0.029;NGT
vs. diabetes P , 0.001; dysglycemia vs.
diabetes P, 0.001), which is attributable
primarily to a decreased static component
of insulin secretion (Fs) across stages
(NGT vs. dysglycemia P = 0.033; NGT vs.
diabetes P , 0.001; dysglycemia vs. dia-
betes P, 0.001). The DIs calculated from
these parameters showed similar steps
across glycemic stages (DI-Ft NGT vs.
dysglycemia P = 0.013; NGT vs. diabetes
P , 0.001; dysglycemia vs. diabetes
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P , 0.001; DI-Fs NGT vs. dysglycemia
P = 0.027; NGT vs. diabetes P , 0.001;
dysglycemia vs. diabetes P , 0.001).
Among the obese adolescents studied,
individualswith dysglycemia anddiabetes
had lower Si and higher HOMA-IR than
NGT subjects (Table 2) (NGT vs. dysglyce-
mia P# 0.03; NGT vs. diabetes P# 0.002)
without a further difference between indi-
viduals with dysglycemia and those with
diabetes. IGI and CPI were significantly
worse in adolescents with type 2 diabetes
than in individuals with dysglycemia or nor-
moglycemia (P# 0.001). DIs derived from
these direct measures of b-cell function
differed stepwise across groups (DI-IGI
NGT vs. dysglycemia P = 0.076; DI-CPI
NGT vs. dysglycemia P = 0.022; all other
comparisons between groups P, 0.001).
In adolescents, Ft and Fs did not differ
between any stages, butFd mirrored IGI
and CPI, with a marked reduction in indi-
viduals with diabetes compared with in-
dividuals with NGT or dysglycemia (Fd
DM vs. NGT P = 0.003;Fd DM vs. dysgly-
cemia P = 0.007). These relationships per-
sistedafter adjustment for insulin sensitivity
(DI-Fd NGT vs. diabetes P , 0.001; dys-
glycemia vs. diabetes P , 0.001).
These differences are presented graph-
ically for themodeledparameters in Fig. 1
and are presented in combinations as DIs
in Fig. 2.
Differences Between Adolescents and
Adults
Statistical tests of differences across clin-
ical stages between adolescents and
adults are presented in the rightmost col-
umns of Table 2, with the key comparison
found in the interaction of age 3 stage.
Among insulin sensitivity measures, only
HOMA-IR differed between age-groups
as a whole (P = 0.011), whereas only Si
demonstrated an interaction between
age-group and glycemic stage (P =
0.044). This difference arose as a result
of age-group differences in the progres-
sion of Si across glycemic stages. Al-
though Si was equal between NGT adults
and adolescents, it was lower in adoles-
cents with dysglycemia than in adults
with dysglycemia (P = 0.025). Because
Si was lower in adults with diabetes
than at other stages, Si was again equal
between age-groups in type 2 diabetes.
An analogous patternwas seen in HOMA-
IR, which was greater (P = 0.004) in
adolescents with dysglycemia owing
to a higher HOMA-IR compared with
NGT. Again, this difference was lost with
diabetes, because adults with type 2 diabe-
tes demonstrated a higher HOMA-IR than
adults with dysglycemia. Summarizing
these observations, significant worsening
of IRcharacterizesyouthswithdysglycemia,
whereas adults show a decrement instead
at the later stage of overt type 2 diabetes.
The two direct measures of insulin se-
cretion, IGI and CPI, both showed differ-
ences between age-groups as awhole (IGI
P = 0.003; CPI P = 0.018), although after
adjusting for insulin sensitivity a group
difference was present only in DI-IGI
(P = 0.048). Although small age-related
differences in IGI and CPI existed at indi-
vidual clinical stages of glycemia, these
differences did not persist after cor-
recting for insulin sensitivity. Neither the
directly measured insulin secretion pa-
rameters nor their DIs showed age-
dependent differences in changes across
glycemic groups (Fig. 2).
The modeled indices of b-cell function
Ft, Fs, and Fd showed differences be-
tween age-groups (P , 0.001 for all),
which persisted after correcting for insu-
lin sensitivity (DI-Ft P , 0.001, DI-Fs
P = 0.03, DI-Fd P = 0.004).Fd was mark-
edly higher in adolescents with NGT and
dysglycemia compared with adults (NGT
P , 0.001; dysglycemia P = 0.005),
whereas the dramatically lowerFd in ad-
olescents with type 2 diabetes did not
differ from their adult counterparts. After
adjusting for insulin sensitivity, NGT ado-
lescents had a slightly higher DI-Fd
(P , 0.001) than adults. Adults showed
stepwise decreases in Ft, Fs, and their
related DIs across glycemic stages. This
pattern was not present in adolescents,
demonstrating age-related variance in
the differences between glycemic stages
(P for age 3 stage: Ft P = 0.015; Fs P =
0.012; DI-Ft P = 0.003; DI-Fs P = 0.01)
(Fig. 2).
CONCLUSIONS
Our findings demonstrate the relative
dominance of IR requiring robust insulin
secretion in the pathogenesis of adoles-
cent dysglycemia, in contrast to progres-
sive b-cell dysfunction driving adult
dysglycemia. We found age-related dif-
ferences in the nature of b-cell dysfunc-
tion across clinical stages of glycemia,
with differences in the progression of Fs
andFd. To our knowledge, this is the first
Figure 1—Comparisonsbetweenadults andadolescents inmodeledparameters of insulin sensitivity
and b-cell function across stages of glycemia. Top left panel: Insulin sensitivity (Si). Top right panel:
Fd. Bottom left panel:Fs. Bottom right panel:Ft. DYS, dysglycemia; T2D, type 2 diabetes. Box plot
presentation, with the bottomand top of the box presenting the 25th and 75th percentiles, respectively,
and the middle line presenting the median. Whiskers present the 5th (bottom) and 95th (top) percen-
tiles; filled circles outside of the whiskers represent individual data points that lie outside this distribu-
tion. Four suchdatapoints are above the scale for theFs adolescent DYS group, as is one data point for
theFt adolescent T2D group. *Indicates statistical difference between adult and adolescent groups.
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study directly comparing measures of in-
sulin responsiveness and b-cell function
between adolescents and adults.
This cohort of obese adolescents ex-
hibited markedly higher insulin secretion
than the adults, a widely recognized fea-
ture of puberty. With this, even obese
adolescents with normoglycemia had a
markedly higher Fd than overweight/
obese adults (Figs. 1 and 2). This differ-
ence in b-cell function between groups
was exaggerated in individuals with dys-
glycemia: where adults showed impaired
Fs and Ft, adolescents continued to
have robust insulin secretion but lower
insulin sensitivity. Interestingly, these dis-
parate combinations of dysfunction dur-
ing dysglycemia (higher IR in adolescents
and lower insulin secretion in adults) re-
sulted in misleadingly comparable DIs.
This is an instance where the DI can mask
important between-group differences in
the contributing components.
The trajectory implied by our cohort (IR
driving the initial failure of glycemic toler-
ance in adolescents) is consistent with a
longitudinal study that showed a marked
decrease of Si in youths progressing from
NGT to IGT compared with nonprogres-
sors, in addition to a 20% reduction of
insulin secretion in progressors (26). An
adult longitudinal study (27) showed
that Pima Indians progressing from NGT
to diabetes had decrements in acute in-
sulin secretory response from NGT to IGT
and from IGT to diabetes, with stepwise
reductions in insulin-stimulated glucose
disposal. Of note, these and other studies
show a combination of insulin secretory
and sensitivity defects in the transition
from NGT to IGT (7,8,10–12,23), but our
comparison in overweight/obese individ-
uals shows in particular a difference in
Fd between adolescents and adults
across the stages of dysglycemia. Prior
longitudinal studies in adolescents have
localized b-cell dysfunction to dynamic
secretion in adolescents (26), whereas
the dominance of dynamic or static secre-
tory dysfunction in adults is less clear (7,9)
and may depend on the type of glucose
intolerance (9,28–30). Our observations
suggest that adolescents andadults achieve
dysglycemia differentlydadolescents
primarily via IR and adults primarily via
b-cell dysfunction. Further work will be
needed to understand how such differ-
ences in function arise, for example
whether they are related principally to
the physiology of puberty or perhaps
reflect an underlying genetic risk that is
brought out by puberty.
Our findings suggest that diabetes pre-
vention should be approached differently
in different age-groups. Adults with predi-
abetesmay benefit more than adolescents
from attempts to increase insulin produc-
tion and secretion. Adolescents with obe-
sity and prediabetes, in contrast, may
benefit in particular from the optimization
of insulin sensitivity because insulin secre-
tion remains robust even during dysglyce-
mia. Given the dramatic difference in
dynamic secretion between adolescents
with dysglycemia and type 2 diabetes, at-
tempts to decrease b-cell demand could
also focus on minimizing the stress upon
this secretion component, for example by
modulating short-term glucose loads.
Several weaknesses of these analyses
should be acknowledged. The two co-
horts we have compared were originally
recruited for studies that were not de-
signed to directly compare the two age-
groups. One consequence of this is the
difference in sample availability from
early time points after glucose ingestion,
and although our evaluations do not sug-
gest that this adversely affected the abil-
ity to model the data, it remains possible
that the between-group comparisons
would differ if identical sampling had
been available. Nevertheless, the oppor-
tunity to apply parallel methods to these
groups provides valuable information
that does not otherwise exist in the liter-
ature. As a consequence of the original
inclusion criteria, youths with normogly-
cemia and dysglycemia had markedly
higher BMI values than adults. Since obe-
sity itself is a contributor to IR (31,32),
these differences may have exaggerated
modeled IR within the adolescent group.
Nevertheless, the concurrent and mark-
edly higher insulin secretion at these
stages affirms that dysglycemia in adoles-
cents arises from relative and not abso-
lute insulin deficiency, driven primarily by
IR.WecalculatedDIs usingmodel-derived
terms that have not been formally dem-
onstrated to exhibit inverse hyperbolic
relationships, but an inverse relationship
is evident in our data even in the absence
of formal testing. Our adult population
had a higher proportion of African Amer-
ican patients, who are recognized to
have a greater insulin response for a given
degree of IR when compared with their
Caucasian counterparts (33–36). How-
ever, if anything, this racial difference
Figure 2—DI curves for normoglycemic adults and adolescents. Insulin sensitivity (Si) is plotted
against different measures of insulin secretion: IGI, static insulin response (i.e.,Fs), dynamic insulin
response (i.e., Fd), and total insulin response (i.e., Ft). The mean DI curves for normoglycemic
individuals are plotted; mean DI6 SD for adults and adolescents at each clinical stage are overlaid.
Black circles, adult with normoglycemia; black squares, adult with dysglycemia; black triangles, adult
with type 2 diabetes; dotted line, adolescent DI; solid line, adult DI; white circles, adolescent with
normoglycemia;white squares, adolescentwith dysglycemia;white triangles, adolescentwith type 2
diabetes.
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would have blunted differences in insulin
secretion between adults and adolescents
and therefore does not detract from our
finding of markedly higher secretion in ad-
olescents. Among our adolescents, there
was a much higher number of individuals
at Tanner 3 stage within the normoglyce-
mic category and none who had diabetes.
This may reflect differences in susceptibil-
ity topubertal stressesonglycemic control,
but we did not have sufficient power
to undertake these comparisons. Direct
study of changes to b-cell function across
Tanner stages would be valuable.
In summary, this study is the first to
directly compare b-cell function and in-
sulin responsivity in adults and adoles-
cents. The present differences suggests
that the two age-groups arrive at similar
clinical stages via differing combinations
of changes in IR and insulin secretion. The
findings of this study reinforce current
treatment and much research in predia-
betes and diabetes in youths, which pri-
marily emphasizes lifestyle modifications
with or without the addition of insulin
sensitizers (37–39). However, the trajec-
tory of b-cell failure suggests that inter-
vention before the development of type 2
diabetes may be especially instrumental
within the adolescent age-group, to pre-
serve relatively robust b-cell function,
and provides a rationale for differential
strategies in diabetes prevention.
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